NanoPhoria Bioscience

Executive Summary

NanoPhoria Bioscience is a preclinical-stage biotechnology company based in Milan, Italy, focused on developing an innovative inhaled Nano-in-Micro delivery platform for cardiovascular diseases. The platform enables precise, tissue-directed therapy for conditions such as heart failure with reduced ejection fraction (HFrEF), addressing high unmet medical needs. Founded in 2016, the company is privately held and has not yet disclosed funding or valuation details. Its approach aims to transform therapeutic delivery by combining nanoparticles within microparticles for inhalation, potentially improving drug targeting and patient compliance. While still in early stages, NanoPhoria's novel platform and focus on cardiovascular disease position it as a candidate for future partnerships and investment as it advances toward clinical development.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead HFrEF Program40% success
• Q3 2026Series A Financing Round55% success
• Q2 2027Strategic Partnership with Cardiovascular Pharma30% success